Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1355 • ACR Convergence 2025
Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
Andreu Fernandez Codina¹, Marie-France Valois², Susan J. Bartlett³, Mishquatul Wahed⁴, Hugues Allard-Chamard⁵, Louis Bessette⁶, Glen Hazlewood⁷, Carol Hitchon⁸, Bindee Kuriya⁹, Vivian Bykerk¹⁰ and Janet Pope¹¹, ¹Western University, London, ON, Canada, ²McGill University, Pointe-Claire, QC, Canada, ³McGill University, Beaconsfield, QC, Canada, ⁴Western University, Windsor, ON, Canada, ⁵Université de Sherbrooke, Sherbrooke, Canada, ⁶Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹University of Toronto - Toronto, Toronto, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹University of Western Ontario, London, ON, Canada
Background/Purpose: The 2023 EULAR recommendations for the management of Rheumatoid Arthritis (RA) emphasizes theimportance of limiting the dose and duration of glucocorticoids (GC) used in…
Abstract Number: 1338 • ACR Convergence 2025
Short-Chain Fatty Acids and Their Gut Microbial Metabolic Pathways Distinguish Rheumatoid Arthritis in Discordant Monozygotic Twins
Rebecca Blank¹, Kevin Bu², Xinyuan Zhang³, Weixi Chen⁴, Ian Cunningham⁴, jeremy sokolove⁵, Lauren Lahey⁶, Adriana Heguy⁴, Rhina Medina⁴, Carles Ubeda⁷, Renuka Nayak⁸, Jiyuan Hu⁴, Adam Cantor⁹, Jakleen Lee⁹, Frances Williams¹⁰, Jose Clemente² and Jose Scher¹¹, ¹NYU Langone Health, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Kings College London, London, United Kingdom, ⁴NYU Grossman School of Medicine, New York, ⁵odyssey, Berwyn, PA, ⁶Stanford, Palo Alto, ⁷Fisabio, Madrid, ⁸University of California, San Francisco (UCSF), San Francisco, CA, ⁹Icahn School of Medicine, New York, ¹⁰Kings College London, London, ¹¹New York University School of Medicine, New York, NY
Background/Purpose: Although genetic factors have been identified in the pathogenesis of RA, the concordance rate in monozygotic (MZ) twins is low, suggesting that other factors…
Abstract Number: 1322 • ACR Convergence 2025
High Rheumatoid Factor Titers and Biologic Persistence in RA: Beyond TNF Inhibitors
Sara Salas Santamaría¹, Marta Chao Moreira², Manuel Juárez³, Marta Novella-Navarro², Pilar Nozal², Ana Martínez², Carolina Tornero⁴, Cristina Bohorquez⁵, Ana Sánchez², Carmen Cámara², Eduardo López², Eugenio de Miguel² and Chamaida Plasencia-Rodríguez², ¹Hospital Universitario La Paz, Miranda de Ebro, Castilla y Leon, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁴Hospital La Paz, Madrid, Spain, ⁵La Paz University Hospital, Alcalá De Henares, Spain
Background/Purpose: Rheumatoid factor (RF), an autoantibody targeting the Fc portion of IgG, is one of the most studied biomarkers in rheumatoid arthritis (RA). High RF…
Abstract Number: 1307 • ACR Convergence 2025
Plasma levels of monounsaturated fatty acids (MUFAs) positively correlate with disease activity in patients with rheumatoid arthritis (RA)
Martha Belury¹, Rachel Cole¹, Steven Pan² and Beatriz Hanaoka², ¹Ohio State University, Columbus, OH, ²Oklahoma University Health Sciences Center, Oklahoma City, OK
Background/Purpose: Rheumatoid arthritis (RA) patients have higher body fat percentages, particularly in the abdominal region, which is associated with increased systemic inflammation. Obesity is associated…
Abstract Number: 1104 • ACR Convergence 2025
Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Kevin Sheng-Kai Ma¹, Rachael Stovall², Jeffrey Sparks³, You Wu², Richard Cheng⁴, Gregory Challener⁵, Hans von Eckstaedt², Bhavik Bansal⁶, Petros Grivas⁷, Steven Chen⁸, Jean Liew⁹ and Namrata Singh⁷, ¹Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States, Philadelphia, PA, ²University of Washington, Seattle, WA, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Washington, Seaattle, WA, ⁵MGH, Boston, MA, ⁶UT Southwestern Medical Centre, Dallas, TX, ⁷University of Washington, BELLEVUE, WA, ⁸Massachusetts General Hospital, Boston, ⁹Boston University, Boston, MA
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) face a higher lifetime burden of cardiovascular disease (CVD) vs the general population with approximately 1.5-2-fold increase in…
Abstract Number: 1030 • ACR Convergence 2025
Predictors of Incident Atrial Fibrillation in Rheumatoid Arthritis Patients: A Population Based Cohort Study
Sarah Pimple¹, Alanna Chamberlain¹, Sara Achenbach², Cynthia Crowson³ and Elena myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Rheumatoid arthritis (RA) has been associated with an increased risk of developing atrial fibrillation (AF). However, recent data on trends in incidence of AF…
Abstract Number: 0926 • ACR Convergence 2025
Discovery and Characterization of SIM0711: a Potent and Selective IRAK4 PROTAC with Improved Efficacy and Safety
Minyun Zhou¹, Peng Gu², Mengyu Wang³, Yuxi Yan², Li Sun³, Yiling Chen³, Xin Wang³, Feng Tang¹, Shunwei Zhu² and Xiaofeng Zhao⁴, ¹State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical group, Nanjing, ²State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Shanghai, China (People's Republic), ³State Key Laboratory of Neurology and Oncology Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic), ⁴State Key Laboratory of Neurology and oncolog Drug Development, Simcere Pharmaceutical Group, Nanjing, China (People's Republic)
Background/Purpose: IRAK4 plays a pivotal role in the innate immune response by acting downstream of Toll-like receptors (TLRs) and the interleukin-1 receptor (IL-1R), with both…
Abstract Number: 0836 • ACR Convergence 2025
Growth Differentiation Factor-15 Predicts Frailty and Death in Rheumatoid Arthritis
Katherine Wysham¹, Hannah Brubeck², Aaron Baraff², Christian Lood³, Punyasha Roul⁴, Bryant England⁵, Beth Wallace⁶, Grant Cannon⁷, Gary Kunkel⁸, Ted Mikuls⁵, Patti Katz⁹, Dolores Shoback¹⁰, Jose Garcia¹¹, Ariela Orkaby¹², Joshua Baker¹³ and Tate Johnson⁵, ¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³University of Washington, Seattle, WA, ⁴UNMC, Omaha, NE, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁷University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁸University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁹UCSF, San Rafael, CA, ¹⁰San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, ¹¹VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ¹²VA Boston Healthcare System & Division of Aging, Brigham and Women’s Hospital, Harvard Medical School & VA Geriatrics Research Education and Clinical Center, Boston, MA, ¹³University of Pennsylvania, Philadelphia, PA
Background/Purpose: RA is associated with premature aging and frailty. Growth differentiation factor-15 (GDF-15) is a biomarker that increases in response to cellular stress and inflammation…
Abstract Number: 0774 • ACR Convergence 2025
Longitudinal peripheral blood multi-omic profiling in at-risk individuals uncovers immune signatures and predictive models for future rheumatoid arthritis conversion
Jun Inamo¹, Aleksandra Bylinska², Miles Smith², Lauren Vanderlinden³, Christian Wright⁴, Tayte Stephens⁵, Marie Feser⁶, Christopher Striebich⁷, James O'Dell⁸, Jeffrey Sparks⁹, John Davis¹⁰, Jonathan Graf¹¹, Maureen McMahon¹², Elizabeth Solow¹³, Lindsy Forbess¹⁴, Athan Tiliakos¹⁵, David Fox¹⁶, Maria I. Danila¹⁷, Diane Lewis. Horowitz¹⁸, Jonathan Kay¹⁹, Judith James², V. Michael Holers²⁰, Kevin Deane²¹, Joel Guthridge² and Fan Zhang²², ¹University of Colorado School of Medicine, Aurora, CO, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³University of Colorado Anschutz Medical Campus, Monument, CO, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵University of Oklahoma Health Science Center, Oklahoma City, OK, ⁶University of Colorado Anschutz Medical Campus, Aurora, CO, ⁷University of Colorado, Aurora, CO, ⁸University of Nebraska Medical Center, Omaha, NE, ⁹Brigham and Women's Hospital, Boston, MA, ¹⁰Mayo Clinic, Rochester, MN, ¹¹UCSF, San Francisco, CA, ¹²UCLA David Geffen School of Medicine, Los Angeles, CA, ¹³UT Southwestern Medical Center, Dallas, TX, ¹⁴Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁵Emory University, Roswell, GA, ¹⁶University of Michigan, Dexter, MI, ¹⁷University of Alabama at Birmingham, Birmingham, ¹⁸Northwell Health, New Hyde Park, ¹⁹UMass Chan Medical School, Worcester, MA, ²⁰University of Colorado Anschutz Medical Campus, Aurora, ²¹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ²²The University of Colorado, Aurora, CO

Background/Purpose: Seropositive rheumatoid arthritis (RA) has an at-risk stage identifiable by elevations of antibodies to cyclic citrullinated peptide (CCP). Identifying the immunologic factors that distinguish…
Abstract Number: 0491 • ACR Convergence 2025
Association of Short Chain Fatty Acids and Diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study
Kaci French¹, Luz Alvarado², Rebecca Haberman³ and Rebecca Blank³, ¹NYU Langone, New York, NY, ²NYU Langone, New York, ³NYU Langone Health, New York, NY
Background/Purpose: Diet, the gut microbiome, and gut microbial metabolites have been implicated in rheumatoid arthritis (RA) development and modulation. Seafood based-omega-3 fatty acids modulate inflammatory…
Abstract Number: 0475 • ACR Convergence 2025
Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada
Cristiano Moura¹, Luck Lukusa², Denis Choquette³, Gilles Boire⁴, Nathalie Carrier⁵, Autumn Neville² and Sasha Bernatsky⁶, ¹Research Institute of the McGill University Health Center, Montréal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, Canada, ³Institut de Rhumatologie de Montréal, Saint-Donat-de-Montcalm, Canada, ⁴Retired, Sherbrooke, QC, Canada, ⁵Centre integré universitaire de santé et de services sociaux de l’Estrie – Centre hospitalier universitaire de Sherbrooke (CIUSSS de l’Estrie-CHUS), Sherbrooke, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: In April 2022, the Canadian province of Quebec introduced a mandatory non-medical switch to biosimilars for persons on bio-originators to manage healthcare costs. Our…
Abstract Number: 0459 • ACR Convergence 2025
Risk Factors for Acute Exacerbation in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease
Rinko Katsuda¹, Akiko Kitagawa¹, Masayuki Azukizawa², Musuzu Fujimori¹ and Tetsuji Kawamura³, ¹Department of Rheumatology, NHO Himeji Medical Center, Japan, Himeji, Japan, ²Department of Orthopaedic Surgery, NHO Himeji Medical Center, Japan, Himeji, Japan, ³Department of Respiratory Medicine, NHO Himeji Medical Center, Japan, Himeji, Japan
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a common and serious extra-articular manifestation of RA, contributing to ~10% of RA-related mortality. Acute exacerbation (AE)…
Abstract Number: 0442 • ACR Convergence 2025
Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort
Charis Meng¹, Marie-France Valois², Caci Julia³, Yvonne Lee⁴, Bindee Kuriya⁵, Gilles Boire⁶, Hugues Allard-Chamard⁷, Carol Hitchon⁸, Louis Bessette⁹, Glen Hazlewood¹⁰, Carter Thorne¹¹, Susan J. Bartlett¹², Janet Pope¹³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²McGill University, Pointe-Claire, QC, Canada, ³Hospital for Special Surgery, New York, ⁴Northwestern University, Chicago, IL, ⁵Mount Sinai Health, Toronto, Canada, ⁶Retired, Sherbrooke, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Manitoba, Winnepeg, Canada, ⁹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²McGill University, Beaconsfield, QC, Canada, ¹³University of Western Ontario, London, ON, Canada
Background/Purpose: A third of patients with early (e)RA report pain outside the joint or non-articular pain (NAP) despite RA treatment(1). NAP, both regional and widespread,…
Abstract Number: 0369 • ACR Convergence 2025
Real-World Persistence of Janus Kinase Inhibitors in Biologic-Experienced Patients with Rheumatoid Arthritis
Jeffrey Curtis¹, Emily Holladay², Nick McCormick³, Yujie Su⁴, Fenglong Xie¹ and Alexis Dineen⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Edmond, OK, ³Auburn University, Auburn, AL, ⁴University of Alabama at Birimingham, Birmingham, AL, ⁵Self, Portola Valley, CA
Background/Purpose: Over the last decade, Janus kinase inhibitors (JAKs) for RA have been increasingly used as a treatment option for patients who do not respond…
Abstract Number: 0197 • ACR Convergence 2025
Rheumatoid arthritis (RA) patients who screen positive for anxiety, depression, and/or fibromyalgia are more likely to report problems with sleeping, memory, and/or social activities than to have an abnormal rheumatoid factor or ACPA
Theodore Pincus¹, Juan Schmukler¹ and Tengfei Li², ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: A symptom checklist and screening indices for anxiety (ANX), depression (DEP), and/or fibromyalgia (FM) on patient questionnaires such as a multidimensional health assessment questionnaire…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].